miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
In this study, we used HER2-positive SKBR3, HER2-negative MCF-7, and their CD44+ CD24- phenotype mammospheres SKBR3-S and MCF-7-S to verify. Our results demonstrated that miR-200c was weakly expressed in breast cancer cell lines and cell line stem cells. Overexpression of miR-200c resulted in a significant reduction in the number of tumour spheres formed and the population of CD44+ CD24- phenotype mammospheres in SKBR3-S. Combining miR-200c with trastuzumab can significantly reduce proliferation and increase apoptosis of SKBR3 and SKBR3-S. Overexpression of miR-200c also eliminated its downstream target genes. These genes were highly expressed and positively related in breast cancer patients. Overexpression of miR-200c also improved the malignant progression of SKBR3-S and SKBR3 in vivo. miR-200c plays an important role in the maintenance of the CSC-like phenotype and increases drug sensitivity to trastuzumab in HER2+ cells and stem cells.
PMID: 31599500 [PubMed - as supplied by publisher]
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tang H, Song C, Ye F, Gao G, Ou X, Zhang L, Xie X, Xie X Tags: J Cell Mol Med Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | HER2 | Herceptin | Molecular Biology | Stem Cell Therapy | Stem Cells | Study